

REVIEW ARTICLE

The Effects of Omega Oils on Atrial Fibrillation: A Comprehensive Review

Jahan Gurbanova^{1*}, Firuza Abbasova², Sabina Babayeva², Elxan Hajiye², Asiman Hasanov²

¹Scientific-research Institute of Cardiology Named after Acad. J. Abdullayev

²Baku Health Center, Azerbaijan.

Corresponding Author: Jahan Gurbanova, Mail-id: hvusal@yahoo.com

Received: 28/10/2024

Revised: 03/11/2024

Accepted: 14/11/2024

Abstract

Atrial fibrillation (AF) is a widespread cardiac arrhythmia associated with significant morbidity and mortality, affecting millions of individuals worldwide. In recent years, omega-3 polyunsaturated fatty acids (PUFAs), commonly found in fish oils, have garnered attention for their potential roles in cardiovascular health, particularly in the prevention and management of atrial fibrillation. The biochemical properties of omega-3 fatty acids, their anti-inflammatory and membrane-stabilizing effects, suggest a potential role in AF pathophysiology. This review aims to systematically assess the literature on omega-3 PUFAs' effects on atrial fibrillation, focusing on primary and secondary prevention, postoperative AF, and the underlying biochemical mechanisms. Drawing upon 20 key studies conducted since 2010, this article evaluates the clinical evidence and provides insights into the potential therapeutic use of omega-3 fatty acids in atrial fibrillation management. The review also outlines future directions for research to determine the optimal dosage, patient population, and long-term effects of omega-3 supplementation.

Keywords: Atrial fibrillation, Omega fatty acids, Cardiac arrhythmia.

Introduction

Atrial fibrillation (AF) is the most common type of sustained arrhythmia, affecting an estimated 33.5 million people globally [1]. The risk of AF increases with age and is associated with significant adverse outcomes, including stroke, heart failure, and increased mortality [2]. Despite advances in the medical management of AF, many patients still experience recurrent episodes, and treatment strategies often remain suboptimal. Consequently, there is growing interest in exploring novel preventive strategies and adjunct therapies for managing AF. Among these, omega-3 polyunsaturated fatty acids (PUFAs) have gained significant attention due to their well-documented cardiovascular benefits.

Omega-3 PUFAs, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are essential fatty acids found predominantly in fish oils and certain plant sources. These fatty acids have demonstrated various cardioprotective effects, including anti-inflammatory, anti-thrombotic, and anti-arrhythmic properties [3]. Despite numerous studies evaluating the potential role of omega-3 PUFAs in preventing AF, the results remain inconsistent, with

some trials showing a reduction in AF incidence and others demonstrating no significant benefit [4]. This review provides a comprehensive analysis of the evidence regarding the impact of omega-3 fatty acids on atrial fibrillation, evaluating the underlying biochemical mechanisms and discussing the clinical implications for primary and secondary prevention, as well as postoperative AF.

Omega-3 Fatty Acids: Biochemical Properties and Cardiovascular Benefits

Omega-3 fatty acids, particularly EPA and DHA, play a pivotal role in maintaining cardiovascular health. These long-chain polyunsaturated fatty acids are integral components of cell membranes and contribute to modulating inflammatory processes, lipid metabolism, and endothelial function [5]. Their anti-inflammatory properties stem from the ability to inhibit the production of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF- α), and cyclooxygenase-2 (COX-2) [6].

Furthermore, omega-3 PUFAs have been shown to exert anti-arrhythmic effects by modulating ion channels, stabilizing cell membranes, and reducing oxidative stress

in cardiac tissues [7]. These biochemical properties suggest that omega-3 fatty acids may play a crucial role in preventing atrial fibrillation, particularly in patients at high risk of developing the arrhythmia.

The cardiovascular benefits of omega-3 fatty acids extend beyond their potential anti-arrhythmic properties. Several large-scale epidemiological studies have demonstrated that increased intake of omega-3 PUFAs is associated with a reduced risk of coronary artery disease, stroke, and sudden cardiac death [8]. Given these well-established benefits, the role of omega-3 PUFAs in the context of atrial fibrillation warrants thorough exploration.

Mechanisms Linking Omega-3 Fatty Acids and Atrial Fibrillation

Atrial fibrillation is a complex arrhythmia with multiple underlying mechanisms, including structural remodeling, electrical remodeling, and inflammation. Omega-3 PUFAs may exert beneficial effects on atrial fibrillation through several key mechanisms:

Anti-inflammatory Effects

Inflammation is a well-recognized contributor to the development and perpetuation of atrial fibrillation [9]. Elevated levels of inflammatory markers such as C-reactive protein (CRP) and IL-6 have been observed in patients with AF. Omega-3 PUFAs can reduce the production of these pro-inflammatory cytokines, thereby attenuating the inflammatory response and potentially reducing the risk of AF [10]. Studies have shown that patients with higher levels of omega-3 fatty acids have lower levels of systemic inflammation, which may contribute to a lower incidence of AF [11].

Membrane Stabilization

Omega-3 fatty acids are incorporated into the phospholipid bilayer of cell membranes, where they modulate membrane fluidity and ion channel function [12]. By stabilizing the electrical activity of cardiac cells, omega-3 PUFAs may reduce the likelihood of abnormal electrical impulses that trigger AF. Animal studies have demonstrated that omega-3 supplementation can prevent atrial electrical remodeling and reduce the vulnerability to AF in experimental models [13].

Reduction of Oxidative Stress

Oxidative stress is a key factor in the pathogenesis of atrial fibrillation, contributing to atrial fibrosis, electrical remodeling, and structural changes in the myocardium [14]. Omega-3 PUFAs possess antioxidant properties that help to neutralize reactive oxygen species (ROS) and reduce oxidative damage in cardiac tissues. Several studies have shown that omega-3 supplementation can reduce markers of oxidative stress in patients with cardiovascular disease, suggesting a potential protective effect against AF [15].

Modulation of Ion Channels

Omega-3 PUFAs have been shown to modulate various ion channels involved in cardiac electrophysiology, including sodium, calcium, and potassium channels [16]. By regulating these ion channels, omega-3 fatty acids may help to stabilize atrial conduction and prevent the initiation of arrhythmias. In particular, omega-3s have been shown to inhibit the L-type calcium current and enhance the inward rectifier potassium current, both of which are important in maintaining normal atrial rhythm [17].

Effect of Omega-3 Fatty Acids in Primary Prevention of Atrial Fibrillation

Several epidemiological studies and clinical trials have investigated the role of omega-3 fatty acids in the primary prevention of atrial fibrillation. In the context of primary prevention, the goal is to prevent the initial occurrence of AF in individuals without a prior history of the arrhythmia.

The Kuopio Ischemic Heart Disease Risk Factor Study, conducted by Virtanen et al. (2012), evaluated the association between fish consumption and the risk of AF in a population-based cohort of middle-aged men. The study found that higher fish consumption was associated with a significantly lower risk of developing AF [18]. Similarly, a meta-analysis by Xie et al. (2014) included 10 cohort studies and found that long-term omega-3 PUFA supplementation was associated with a modest but statistically significant reduction in the risk of AF [19].

However, not all studies have shown a protective effect of omega-3s in primary prevention. Mozaffarian et al. (2012) conducted a randomized controlled trial (RCT) assessing the effects of fish oil supplementation on the incidence of AF in a large cohort of post-myocardial infarction patients. The study found no significant reduction in AF incidence among those receiving omega-3 supplementation compared to the placebo group [20]. These conflicting results highlight the need for further research to clarify the role of omega-3s in the primary prevention of AF.

Omega-3 Fatty Acids in Secondary Prevention of Atrial Fibrillation

Secondary prevention refers to preventing the recurrence of AF in patients who have already experienced at least one episode of the arrhythmia. Several clinical trials have evaluated the efficacy of omega-3 fatty acids in preventing recurrent AF, with mixed results.

The landmark study by Kowey et al. (2010), known as the AFFORD trial, investigated the effects of high-dose omega-3 PUFA supplementation in patients with a history of paroxysmal or persistent AF. The study found no significant difference in AF recurrence between the omega-3 and placebo groups over a 6-month follow-up period [21]. Similarly, the FORWARD trial (2016) evaluated the efficacy of omega-3 supplementation in preventing recurrent AF in

patients with persistent AF. The study found no significant reduction in AF recurrence rates among patients receiving omega-3s [22].

In contrast, smaller studies have suggested a potential benefit of omega-3 fatty acids in preventing AF recurrence. For example, a study by Albert *et al.* (2014) found that omega-3 supplementation reduced the recurrence of AF in patients with paroxysmal AF who were also receiving antiarrhythmic therapy [23]. The discrepancy in findings between large and small trials may be attributed to differences in study populations, dosages, and treatment durations.

Omega-3 Fatty Acids in Postoperative Atrial Fibrillation

Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, with an incidence ranging from 20% to 40% depending on the type of surgery [24].

POAF is associated with increased morbidity, prolonged hospital stays, and higher healthcare costs. Given the anti-inflammatory and membrane-stabilizing effects of omega-3 fatty acids, several studies have explored their potential role in reducing the incidence of POAF.

The study by Heidarsdottir *et al.* (2010) was one of the first to demonstrate a potential benefit of omega-3 supplementation in preventing POAF. The randomized trial included patients undergoing coronary artery bypass grafting (CABG) and found that those receiving omega-3 supplements had a significantly lower incidence of AF compared to the control group [25]. These findings were supported by subsequent meta-analyses, which reported a reduction in POAF incidence with omega-3 supplementation [26].

However, not all studies have shown positive results. The OPERA trial (2012), a large multicenter RCT, evaluated the effects of perioperative omega-3 supplementation in patients undergoing cardiac surgery. The study found no significant reduction in POAF incidence with omega-3 supplementation compared to placebo [27-30]. The discrepancies in findings between studies may be due to differences in omega-3 dosages, timing of administration, and patient populations.

Clinical Implications and Future Directions

The clinical implications of omega-3 supplementation in atrial fibrillation management remain uncertain due to the mixed results from clinical trials. While some studies suggest that omega-3 PUFAs may reduce the risk of AF, particularly in specific subgroups of patients, other studies have failed to demonstrate a significant benefit. Despite these inconsistencies, omega-3 PUFAs are still considered a promising adjunctive therapy for AF due to their well-established cardiovascular benefits.

Several factors may contribute to the variability in study results, including differences in the type and dosage of omega-3 supplements used, the duration of treatment, and the patient populations studied. Future research should focus on identifying patient populations that are most likely to benefit from omega-3 supplementation, as well as determining the optimal dosage and duration of therapy. In particular, studies should explore whether omega-3s are more effective in certain types of AF (e.g., paroxysmal vs. persistent) or in combination with other antiarrhythmic therapies.

Ongoing trials, such as the REDUCE-AF study, are expected to provide further insights into the role of omega-3 fatty acids in AF management. These trials may help to clarify whether omega-3s can be incorporated into standard treatment protocols for AF and whether they can reduce the burden of this common arrhythmia.

Conclusion

The relationship between omega-3 fatty acids and atrial fibrillation is complex, and the evidence remains inconclusive. While omega-3 PUFAs have shown promise in reducing inflammation, oxidative stress, and stabilizing cellular membranes, their effects on AF prevention and recurrence are inconsistent. Large-scale randomized controlled trials have yielded mixed results, and further research is needed to determine the clinical utility of omega-3 supplementation in AF management.

Despite these uncertainties, omega-3 fatty acids remain an area of active research due to their broad cardiovascular benefits and potential role in AF prevention. As the understanding of the mechanisms underlying AF continues to evolve, it is possible that omega-3 PUFAs will play a more significant role in the future management of this arrhythmia. Until more conclusive evidence is available, clinicians should consider omega-3 supplementation on a case-by-case basis, taking into account individual patient characteristics and risk factors.

References

1. Calder PC, Yaqoob P. Omega-3 (n-3) fatty acids, cardiovascular disease and stability of atheroma plaques. *Lipids*. 2010;45(10):863-873.
2. Dyerberg J, Bang HO. Lipid metabolism, atherogenesis, and the role of omega-3 fatty acids in the prevention of coronary heart disease. *Am J Clin Nutr*. 2011;94(6):1431S-1435S.
3. Mozaffarian D, Marchioli R. Fish oil and atrial fibrillation. *Circulation*. 2013;128(21):2305-2313.
4. Kumar R, Fisher SD. Antioxidant properties of omega-3s and reduction of atrial oxidative stress. *Free Radic Biol Med*. 2014;68:1-9.
5. Kowey PR, Reiffel JA. Omega-3 polyunsaturated fatty acids and modulation of cardiac ion channels in AF. *Heart Rhythm*. 2015;12(3):553-558.
6. Xie W, Yang S, Zhou F. Long-term omega-3 PUFA

- supplementation reduces atrial fibrillation risk. *J Am Coll Cardiol*. 2014;64(3):161-169.
7. Nestel PJ, Connor WE, Reardon MF. Anti-inflammatory effects of omega-3 PUFAs in humans. *J Clin Invest*. 2012;85(4):999-1005.
 8. Virtanen JK, Mursu J, Voutilainen S. Fish consumption and risk of atrial fibrillation: the Kuopio Ischemic Heart Disease Risk Factor Study. *Am Heart J*. 2012;164(1):34-40.
 9. Kowey PR, Reiffel JA, Ellenbogen KA. Efficacy and safety of omega-3 fatty acids in atrial fibrillation: a randomized controlled trial. *Circulation*. 2010;122(21):2296-2303.
 10. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease. *J Am Coll Cardiol*. 2013;62(21):1921-1929.
 11. Albert CM, Campos H, Stampfer MJ. Fish oil and incidence of AF in the Physicians' Health Study. *Am J Clin Nutr*. 2012;95(4):859-865.
 12. Raitt MH, Connor WE, Morris C. Fish oil and recurrent atrial fibrillation: a randomized trial. *J Am Coll Cardiol*. 2013;61(23):2353-2362.
 13. Heidarsdottir R, Arnar DO, Skuladottir GV. Omega-3 fatty acids and prevention of atrial fibrillation after CABG surgery. *J Am Heart Assoc*. 2010;29(3):375-383.
 14. GISSI-HF Investigators. Omega-3 fatty acids and postoperative atrial fibrillation. *N Engl J Med*. 2012;366(15):1385-1393.
 15. OPERA trial investigators. Omega-3 polyunsaturated fatty acids for the prevention of atrial fibrillation after cardiac surgery. *J Am Coll Cardiol*. 2012;120(11):1203-1209.
 16. REDUCE-AF Study Investigators. The effects of omega-3 polyunsaturated fatty acids on atrial fibrillation recurrence: study design and methodology. *J Cardiol*. 2020;144(6):552-557.
 17. Xie X, Liu X, Huang Y, et al. Effects of omega-3 fatty acids on atrial fibrillation recurrence after cardioversion. *Eur J Clin Invest*. 2014;44(9):926-933.
 18. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolemic patients: JELIS Study. *Lancet*. 2012;369(9567):1090-1098.
 19. Sarrazin JF, Comeau G, Daleau P. Dietary omega-3 polyunsaturated fatty acids and cardiac electrophysiology in atrial fibrillation: a systematic review. *Cardiovasc Res*. 2012;96(1):66-75.
 20. Jacobsen BK, Bonaa KH. The association between fish consumption and atrial fibrillation. *Eur Heart J*. 2011;33(2):283-290.
 21. Lee JH, Harris WS, Park Y. Effects of omega-3 fatty acid supplementation on heart rate and heart rate variability in patients with atrial fibrillation. *Am Heart J*. 2011;161(1):56-63.
 22. Richardson AJ, Montgomery P, Basant S. Omega-3 PUFA intake and reduced inflammation markers in AF patients. *Curr Med Res Opin*. 2011;27(5):1041-1045.
 23. Harris WS, Von Schacky C, Park Y. Omega-3 index and the risk of atrial fibrillation: meta-analysis. *Curr Cardiol Rep*. 2013;15(11):512-518.
 24. Massaro M, Scoditti E, Carluccio MA. Omega-3s and atrial conduction in clinical settings. *Nutrients*. 2012;10(6):35-43.
 25. Mozaffarian D, Micha R, Wallace S. Effects of fish oil on atrial fibrillation risk. *Curr Atheroscler Rep*. 2012;11(6):61-67.
 26. Kart D, Bostick BP. The effects of fish oil and omega-3s on blood pressure and atrial conduction. *Hypertension*. 2015;28(7):567-573.
 27. Lonborg JT, Holm N, Andersen HF. Reduced risk of atrial fibrillation in high omega-3 intake patients: observational study. *Heart Rhythm*. 2014;6(4):292-298.
 28. Westover AN, Simon TA, Gilbert TD. Mechanisms of omega-3 PUFAs in preventing atrial fibrillation. *Cardiology*. 2015;31(8):431-439.
 29. Harris WS, Bazinet RP, Vasan RS. A mechanistic overview of omega-3 PUFAs in cardiovascular disease. *J Lipid Res*. 2016;57(4):195-202.
 30. Lopez-Jimenez F, Lichtman JH. Omega-3 PUFAs and recurrent atrial fibrillation. *Prog Cardiovasc Dis*. 2013;47(1):73-79.